Dr Luis Tavernelli
- Research Associate (Parasitology)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Tavernelli, L. E. et al. (2024) Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 ( Tc BDF2) using a fluorescence polarization-based high-throughput assay. Antimicrobial Agents and Chemotherapy, 68(8), 00243-24. (doi: 10.1128/aac.00243-24) (PMID:39028190) (PMCID:PMC11304739)
Simwela, N. V. et al. (2023) A conserved metabolic signature associated with response to fast-acting anti-malarial agents. Microbiology Spectrum, 11(6), e0397622. (doi: 10.1128/spectrum.03976-22) (PMID:37800971) (PMCID:PMC10714989)
Pezza, A. et al. (2022) Essential bromodomain TcBDF2 as a drug target against Chagas disease. ACS Infectious Diseases, 8(5), pp. 1062-1074. (doi: 10.1021/acsinfecdis.2c00057) (PMID:35482332)
Alonso, V. L., Tavernelli, L. E., Pezza, A., Cribb, P., Ritagliati, C. and Serra, E. (2019) Aim for the readers! Bromodomains as new targets against Chagas’ disease. Current Medicinal Chemistry, 26(36), pp. 6544-6563. (doi: 10.2174/0929867325666181031132007) (PMID:30378479)
Tavernelli, L. E., Motta, M. C. M., Gonçalves, C. S., da Silva, M. S., Elias, M. C., Alonso, V. L., Serra, E. and Cribb, P. (2019) Overexpression of Trypanosoma cruzi High Mobility Group B protein (TcHMGB) alters the nuclear structure, impairs cytokinesis and reduces the parasite infectivity. Scientific Reports, 9, 192. (doi: 10.1038/s41598-018-36718-0) (PMID:30655631) (PMCID:PMC6336821)
Tavernelli, L. E. et al. (2024) Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 ( Tc BDF2) using a fluorescence polarization-based high-throughput assay. Antimicrobial Agents and Chemotherapy, 68(8), 00243-24. (doi: 10.1128/aac.00243-24) (PMID:39028190) (PMCID:PMC11304739)
Simwela, N. V. et al. (2023) A conserved metabolic signature associated with response to fast-acting anti-malarial agents. Microbiology Spectrum, 11(6), e0397622. (doi: 10.1128/spectrum.03976-22) (PMID:37800971) (PMCID:PMC10714989)
Pezza, A. et al. (2022) Essential bromodomain TcBDF2 as a drug target against Chagas disease. ACS Infectious Diseases, 8(5), pp. 1062-1074. (doi: 10.1021/acsinfecdis.2c00057) (PMID:35482332)
Alonso, V. L., Tavernelli, L. E., Pezza, A., Cribb, P., Ritagliati, C. and Serra, E. (2019) Aim for the readers! Bromodomains as new targets against Chagas’ disease. Current Medicinal Chemistry, 26(36), pp. 6544-6563. (doi: 10.2174/0929867325666181031132007) (PMID:30378479)
Tavernelli, L. E., Motta, M. C. M., Gonçalves, C. S., da Silva, M. S., Elias, M. C., Alonso, V. L., Serra, E. and Cribb, P. (2019) Overexpression of Trypanosoma cruzi High Mobility Group B protein (TcHMGB) alters the nuclear structure, impairs cytokinesis and reduces the parasite infectivity. Scientific Reports, 9, 192. (doi: 10.1038/s41598-018-36718-0) (PMID:30655631) (PMCID:PMC6336821)